Mohamad A Cherry

Learn More
Dear Editor, Erlotinib is an epidermal growth factor receptor smallmolecule inhibitor and is FDA approved for the treatment of lung and pancreatic cancers. In preclinical study [1, 2], in vitro colony culture assays revealed that erlotinib at micromolar concentrations effectively suppressed the growth and expansion of polycythemia vera (PV) hematopoietic(More)
The myelodysplastic syndromes (MDS) are a group of clonal hematopoietic stem cell disorders characterized by cytopenias, dysplastic changes in the hematopoietic precursors, and an increased risk of evolving into acute leukemia. Treatment for patients with MDS ranges from supportive care with blood products and/or growth factors up to allogeneic stem cell(More)
Granulocytic sarcoma, also known as chloroma or myeloid sarcoma, is a pathologic term generally used to describe extramedullary solid tumors composed of myeloblasts. Rarely, it can occur as an isolated finding of acute myeloid leukemia (AML), without bone marrow or blood involvement. Primary involvement of the urinary tract without evidence of leukemia is(More)
6621 Background: Essential thrombocythemia (ET) and polycythemia vera (PV) are chronic myeloproliferative neoplasms (MPN). Patients (pts) are at risk of thrombohemorrhagic complications for which they are often treated with different agents. Previous studies suggested that the risk of secondary malignancy (SM) may be increased in pts with PV or ET treated(More)
Background. We hereby describe what we believe to be the first reported case of t (14; 15) (q32; q13) associated with acute myeloid leukemia (AML). Methods. PubMed, Embase, and OVID search engines were used to review the related literature and similar published cases. Case. A47-year-old female presented in December 2011 with AML (acute myelomonocytic(More)
Venous thromboembolism (VTE) is a preventable disease, yet it is one of the leading causes of death among patients with cancer. Improving risk stratification mechanisms will allow us to personalize thrombo-prophylaxis strategies. We sought to evaluate Collagen and Thrombin Activated Platelets (COAT-platelets) as well as protein C and factor VIII as(More)